Metaplastic breast cancer (MpBC) is a rare and aggressive form of breast cancer with a triple-negative phenotype. It shows a poor response to cytotoxic agents and is associated with poor median overall survival of less than a year, even with chemotherapy. 1 This Journal Watch discusses the study details (table 1) and key findings of “ A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609) ,” a study published in Clinical Cancer Research 2022 . 2 What was the rationale of the study?
The limited treatment options, poor prognosis, and a high tumoral PD-L1 expression and tumor-infiltrating lymphocytes in some cases 3 have led researchers to study the effect of immunotherapies in MpBC patients. How was the study conducted? Table 1 . Study details…
